GLPwatch
Observational Study of ASCVD Risks of Type 2 Diabetes in East China
NCT04866667 · Completed
Last updated 2026-05-28This study will observe adults with type 2 diabetes in East China to track the development of heart disease and examine factors like the medication liraglutide.
Status Completed The study has finished.
Type Observational
Participants 316 people
Who can join Ages 18+ · all sexes
Timeline Started 2021-05 · est. completion 2024-05
Where 1 site · China
What this study is testing ClinicalTrials.gov NCT04866667 ↗
Description as written by the study sponsor.
The aim of this study is to screen patients with type 2 diabetes with high risk of cardiovascular disease, and intervene with or without Glucagon like peptide-1 receptor agonists.
| Main thing measured | New-onset cardiovascular events |
|---|---|
| Sponsor | Zhejiang Provincial People's Hospital |
| Conditions studied | Type 2 Diabetes Mellitus, Arteriosclerotic Cardiovascular Disease, Liraglutide |
| GLP-1 drugs | liraglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04866667 ↗